| Product NDC: | 10019-925 | 
| Proprietary Name: | IFOSFAMIDE | 
| Non Proprietary Name: | IFOSFAMIDE | 
| Active Ingredient(s): | 1 g/20mL & nbsp; IFOSFAMIDE | 
| Administration Route(s): | INTRAVENOUS | 
| Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION | 
| Coding System: | National Drug Codes(NDC) | 
| Product NDC: | 10019-925 | 
| Labeler Name: | Baxter Healthcare Corporation | 
| Product Type: | HUMAN PRESCRIPTION DRUG | 
| FDA Application Number: | NDA019763 | 
| Marketing Category: | NDA | 
| Start Marketing Date: | 19881230 | 
| Package NDC: | 10019-925-01 | 
| Package Description: | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-925-01) > 20 mL in 1 VIAL, SINGLE-DOSE (10019-925-82) | 
| NDC Code | 10019-925-01 | 
| Proprietary Name | IFOSFAMIDE | 
| Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-925-01) > 20 mL in 1 VIAL, SINGLE-DOSE (10019-925-82) | 
| Product NDC | 10019-925 | 
| Product Type Name | HUMAN PRESCRIPTION DRUG | 
| Non Proprietary Name | IFOSFAMIDE | 
| Dosage Form Name | INJECTION, POWDER, FOR SOLUTION | 
| Route Name | INTRAVENOUS | 
| Start Marketing Date | 19881230 | 
| Marketing Category Name | NDA | 
| Labeler Name | Baxter Healthcare Corporation | 
| Substance Name | IFOSFAMIDE | 
| Strength Number | 1 | 
| Strength Unit | g/20mL | 
| Pharmaceutical Classes | Alkylating Activity [MoA],Alkylating Drug [EPC] |